Neuland Laboratories Limited CC-Feb26.pdf · 2026-02-09
First question is on the number of active projects that we've seen at the end of this quarter. We've seen in API in terms of commercial one new molecule being added, which we have been speaking about, while al so in the intermediate, we see two molecules being added in the commercial segment. Could you highlight a bit on this opportunity?
So got that. Second question is on the new block of a commercialized molecule that got commercialized last quarter, and as per your commentary, we were supposed to ramp up starting this quarter. But just wanted more clarity on this. Is there a delay in that commercialization process because earlier we had said that there is a capacity constraint and once you've added this 100 metric tons of added capacity, and we've also talked about lumpiness of supply and this. So what exactly is happening on the broader terms if you could make us understand?